Tuesday, March 28, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

NanoViricides, USAMRIID Sign CRADA for Ebola Drug Testing

by Global Biodefense Staff
November 13, 2014
Ebola Virus Countermeasure Development

NanoViricides, Inc. recently announced it has executed a Collaborative Research and Development Agreement for Material Transfer (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

Certain novel anti-Ebola nanomedicine drug candidates recently developed by the NanoViricides will be evaluated by USAMRIID scientists in their BSL-4 facilities for activity against the deadly Ebola virus under this agreement.

“We are very happy to restart our collaboration with USAMRIID for developing an effective drug against the deadly Ebola virus,” said Dr. Eugene Seymour, MD, MPH, CEO of NanoViricides, Inc. “We intend to ship the samples as soon as the synthesis of the new drug candidates is completed.”

The company is now synthesizing test quantities of its novel nanoviricide drug candidates, designed to mimic the host cell receptor onto which the Ebola virus binds to cause an infection. The site at which the virus binds does not change, in spite of mutations.

This approach could allow drug candidates to continue to work in spite of field mutations in the virus, offering a significant advantage over vaccines, antibodies, siRNA, antisense, and several other therapeutic modes, which a virus can overcome due to mutations.

“We are using scalable processes so that we can rapidly transfer synthesis to kg-scale production, which we believe will be sufficient to contain the spread of the current Ebola epidemic,” said Anil R. Diwan, PhD, President and Chairman of the Company, adding, “We believe that the collaboration with USAMRIID will enable timely testing of our candidates in an effort to rapidly zero in on a final drug candidate against Ebola.”

Source: NanoViricides press release, adapted.

Tags: EbolaEmerging ThreatsUSAMRIID

Related Posts

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC